WS
ATXS

Wedbush Securities’s Astria Therapeutics ATXS Stock Holding History

Wedbush Securities’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,197
Closed -$534K – 859
2017
Q3 		$534K Buy
4,197
+4,027
+2,369% +$336K 0.07% 359
2017
Q2 		$14K Buy
+170
New +$14.2K ﹤0.01% 830

Other funds holding ATXS

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wedbush Securities's ATXS Position: Q4 2017 in Review

Wedbush Securities sold out of Astria Therapeutics (ATXS) in Q4 2017, closing a stake of 4,197 shares — an estimated $534K sold.

Wedbush Securities first reported a position in ATXS in Q2 2017 and held it in 2 quarters. The position peaked at $534K in Q3 2017. 25 funds tracked by Wall St. Rank hold ATXS as of Q4 2017.

  • Wedbush Securities reported no remaining Astria Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Wedbush Securities sold 4,197 Astria Therapeutics shares in Q4 2017, an estimated $534K.
  • Wedbush Securities first reported a position in Astria Therapeutics in Q2 2017 and held it in 2 quarters.
  • Wedbush Securities's Astria Therapeutics position peaked at $534K in Q3 2017.
  • 25 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2017.

Based on Wedbush Securities's 13F filing for Q4 2017, filed 9 Feb 2018.